Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients

Fujian Provincial Cancer Hospital

Status and phase: Not yet enrolling; Phase 2

Conditions: Early Breast Cancer; Adjuvant Therapy; Hormone Receptor Positive / HER2-negative Breast Cancer

Treatments: Drug: Dalpiciclib; Drug: Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)

Study type: Interventional

Funder types: Other

Identifiers

NCT07101159

OBU-BC-II-304

Details and patient eligibility

About

This study aims to evaluate the efficacy and safety of adjuvant endocrine therapy combined with dalpiciclib at different doses and durations in patients with hormone receptor (HR)-positive, HER2-negative early-stage breast cancer.

It is a multicenter, prospective clinical study. All enrolled patients will receive either dalpiciclib 125 mg for 2 years or dalpiciclib 100 mg for 3 years, in combination with standard endocrine therapy.

The primary endpoint is 3-year invasive disease-free survival (iDFS).

Enrollment: 200 estimated patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Female breast cancer patients aged ≥ 18 years, who are postmenopausal or premenopausal/perimenopausal;
• Histologically confirmed HR-positive, HER2-negative early-stage breast cancer (immunohistochemical detection shows ER ≥ 10% and/or PR ≥ 10%, HER2 0-1+ or HER2 ++ but negative and non-amplified by FISH or CISH detection);
• Histologically confirmed invasive breast cancer with postoperative pathological stage II-III;
• Patients with or without prior neoadjuvant chemotherapy or adjuvant chemotherapy are eligible for enrollment;
• The maximum time from surgery to enrollment does not exceed 12 months;
• Patients receiving radiotherapy must have recovered from acute radiation reactions, with a washout period of at least 14 days from the end of radiotherapy to enrollment;
• Patients who received previous chemotherapy must have recovered from acute adverse reactions of chemotherapy (graded ≤ 1 according to [CTCAE]) before enrollment, except for alopecia or grade 2 peripheral neuropathy. There must be a washout period of at least 21 days from the last chemotherapy administration to enrollment;
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;
• The main organ function levels must meet the following requirements: Blood routine: Neutrophil count (ANC) ≥ 1.5×10⁹/L; Platelet count (PLT) ≥ 90×10⁹/L; Hemoglobin (Hb) ≥ 90 g/L;Blood biochemistry: Total bilirubin (TBIL) ≤ 2.5×ULN; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 1.5×ULN; Alkaline phosphatase ≤ 2.5×ULN; Blood urea nitrogen (BUN) and creatinine (Cr) ≤ 1.5×ULN;
• 12-lead electrocardiogram: Fridericia-corrected QT interval (QTcF) < 470 ms in females (QTcF calculation formula: QTcF = QT/(RR^1/3));
• Voluntarily participate in this study, sign the informed consent, have good compliance and are willing to cooperate with follow-up.

Exclusion criteria

• Stage IV breast cancer, recurrent or metastatic breast cancer, or inflammatory breast cancer;
• A history of any malignant tumor, or having received anti-tumor treatment or radiotherapy for any malignant tumor in the past, excluding cured malignant tumors such as carcinoma in situ of the cervix, basal cell carcinoma or squamous cell carcinoma of the skin;
• Concurrent participation in other clinical trials;
• Having received blood transfusion or treatment with colony-stimulating factors, etc. within 2 weeks before enrollment;
• Known history of allergy to the components of the drugs in this protocol;
• History of immunodeficiency, including positive HIV test, or suffering from other acquired or congenital immunodeficiency diseases, or having a history of organ transplantation;
• A history of any heart disease, including: angina pectoris; arrhythmia requiring drug treatment or with clinical significance; myocardial infarction; heart failure; any other heart disease judged by the researcher as unsuitable for participating in this trial;
• Pregnant or lactating female patients;
• Any other conditions that the researcher deems make the subject unsuitable for participating in this study.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

200 participants in 2 patient groups

2-Year Dalpiciclib 125 mg + Endocrine Therapy

Experimental group

Description:

Patients will receive dalpiciclib 125 mg orally once daily on days 1-21 of a 28-day cycle for 2 years, in combination with standard endocrine therapy.

Treatment:

Drug: Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)

Drug: Dalpiciclib

Drug: Dalpiciclib

3-Year Dalpiciclib 100 mg + Endocrine Therapy

Experimental group

Description:

Patients will receive dalpiciclib 100 mg orally once daily on days 1-21 of a 28-day cycle for 3 years, in combination with standard endocrine therapy.

Treatment:

Drug: Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)

Drug: Dalpiciclib

Drug: Dalpiciclib